Posts for Ticker ‘ARYX’

Major Secondary Offerings Keep Coming (ALTH, ATAX, ARYX, APPY, GRS, LINE, SGMO, CAR)

Money Stack ImageWe are seeing more and more waves of secondary offerings continue to hit the Street since the stock market has held up. Many stocks are close to near-term highs and it seems they are raising cash in case the opportunity goes away.  Allos Therapeutics, Inc. (NASDAQ: ALTH), America First Tax Exempt Investors, L.P. (Nasdaq: ATAX), ARYx Therapeutics, Inc. (NASDAQ: ARYX), AspenBio Pharma Inc. (NASDAQ: APPY), Gammon Gold, Inc. (NYSE: GRS), LINN Energy, LLC (NASDAQ: LINE), and Sangamo BioSciences, Inc. (Nasdaq: SGMO) have all priced secondary offerings.  Avis Budget Group, Inc. (NYSE: CAR) is one of the pending offerings.
Read More »

Posted on: October 7, 2009 – 11:09 am in Secondary Offering, , , , , , , ,

Day Trader Alerts (AMGN, NVS, MSCS, DRYS, ARYX, XNPT, ARNA, BPZ)

These are some of the top stocks for day traders and active traders to watch based on pre-market and after-hours volume activity with links to more detailed price and volume analysis on each situation at VSInvestor.com:

  • Amgen Inc. (AMGN) is up about 13% on positive Phase III trial results; Novartis Inc. (NYSE: NVS) may be affected negatively.
  • MSC Software Corp. (Nasdaq: MSCS) shares are up as Symphony Technology placed a bid on the company for $360 million.
  • DryShips Inc. (Nasdaq: DRYS) scored a Credit Suisse upgrade on the stock with close a 5% gain.
  • ARYx Therapeutics Inc. (Nasdaq: ARYX) is getting halved after the company’s experimental anticoagulant failed in a late-stage study.
  • xenoport Inc. (NASDAQ: XNPT) shares were down strongly after hours on a secondary offering.  Ditto on Arena Pharmaceuticals Inc. (NASDAQ: ARNA).
  • BPZ Resources Inc. (NYSE: BPZ) is rising after it announced a credit line that will be used to help it fund projects in Peru.

-The 24/7 Wall St. Team

Posted on: July 8, 2009 – 8:10 am in Trading Alert, , , , , , , ,

This Week’s BioHealth & Biotech Top Stories

We saw another exciting week full of news for key developments in drug stocks, biotech stocks, medical device stocks, and other companies involved in various aspects of health care and medicine.  Below are some of the stock tickers we covered over at BioHealthInvestor.com this week:

  • STOCK TICKERS: ABT, BSX, MDT, JNJ, SRDX, ANPI, BAYRY, MAXY, AMGN, CRA, INGN, CELG, MRK, SNY, GSK, AKRX, ARYX

This week we saw another FDA Approval in stents as Abbott’s (NYSE: ABT) XIENCE drug-eluting coronary stent was approved for marketing.  While this is causing a resurgence in stents, this space is about to become highly competitive (stocks covered: ABT, BSX, MDT, JNJ, SRDX, ANPI).  Introgen (NASDAQ: INGN) has a new twist for head and neck cancer… give it a cold, literally.  Celgene Corp. (NASDAQ: CELG) actually won out as a competitor’s bone marrow disease trials failed to meet expectations.  Merck (NYSE: MRK) was an FDA decision winner as it gets to keep its lead on the cervical cancer vaccine market in the U.S. tied up for at least 6-months longer than it was anticipated (stocks covered: MRK, SNY, GSK).

This may be a tiny company, but a patent was awarded in bone marrow and stem cell transplants.  While a biotech turned over its hemophelia treatments to a larger company, hemophelia treatments may be better off now (stocks covered: BAYRY, MAXY, AMGN).  Vaccine awards are going to keep sales up at one small vaccine maker.  One Alzheimer’s Disease treatment that originally had high hopes has bitten the dust.  P&G walked away from a partner this week, killing a tiny biotech (stocks covered: PG, ARYX).

And on the front for reviews:

  • Do you remember all the hype and hopes for synthetic blood?  This looks like the last player has gone on to greener pastures.
  • What is a good investment that has backed way off from highs that should show steady growth in the China health care sector?  We evaluated one potential company for this.

These issues are more stock issues than anything else:

Have a happy and safe LONG Fourth of July weekend.  I think there is a new treatment on the market for burnt hand trauma from fireworks, but the FDA has it on hold until next February.

Jon C. Ogg
July 4, 2008

Posted on: July 4, 2008 – 7:31 am in Biotech, Healthcare, Medical, The Week, , , , , , , , , , , , , , , , ,

IPO FILING: ARYx Therapeutics, Inc. (ARYX, PG)

ARYx THERAPEUTICS, INC. has filed to raise up to $86.25 million in an IPO under the ticker "ARYX" on NASDAQ.  The biotech has secured Morgan Stanley, CIBC World Markets, Jefferies & Co, and Leerink Swann as its underwriters.

The company actually has a fairly unique model developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.  It uses its own "RetroMetabolic Drug Design" technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds.

The lead and most advanced product candidate, ATI-7505, is based on cisapride and has successfully completed Phase 2 clinical trials for the treatment of gastroesophageal reflux disease and symptoms associated with functional dyspepsia; its second product candidate, ATI-5923, is based on warfarin and is currently in Phase 2 proof-of-concept clinical trials for use as an anticoagulant to treat patients at risk for the formation of dangerous blood clots; its third product candidate, ATI-2042, is based on amiodarone and is in Phase 2 clinical trials for the treatment of atrial fibrillation, a form of irregular heartbeat.  Its targets are drug candidates targeting multi-billion dollar markets and it has a worldwide collaboration with Procter & Gamble Pharmaceuticals (NYSE:PG) for the development and commercialization of ATI-7505.

The company’s main revenues appear to be collaborative revenues from P&G as it has no products on the market, so it is still just in clinical stages.  Additional milestone revenue could reach approximately $391 million over the remaining life of the collaboration, of which approximately $216 million could be earned prior to commercialization.

Jon C. Ogg
August 31, 2007

Posted on: August 31, 2007 – 12:05 pm in Biotech, IPOs, , ,